[MANAGEMENT OF VENOUS THROMBOEMBOLISM: WHICH DRUG, WHAT DOSE AND FOR HOW LONG]

Area of Science:

• Cardiology
• Hematology
• Pharmacology

Background:

• Venous thromboembolism (VTE) is a significant cause of illness and death.
• Initial VTE treatment involves three months of anticoagulation, with extended therapy aimed at preventing recurrence.
• Anticoagulation duration is influenced by event provocation, patient gender, oral contraceptive use, and cancer status.

Purpose of the Study:

• To review the use of direct oral anticoagulants (DOACs) in managing venous thromboembolism (VTE).
• To discuss the efficacy and safety of DOACs in various clinical scenarios, including VTE in cancer patients.
• To address emerging issues and evidence gaps concerning DOACs in VTE treatment.

Main Methods:

• Literature review of studies on DOACs for VTE.
• Analysis of clinical scenarios involving anticoagulation duration and patient-specific factors.
• Evaluation of preliminary evidence for DOACs in VTE within cancer patient populations.

Main Results:

• DOACs demonstrate comparable efficacy to warfarin for VTE treatment.
• DOACs are associated with a reduced incidence of major bleeding events compared to warfarin.
• Preliminary data suggest DOAC efficacy in VTE for cancer patients, though further evidence is needed.

Conclusions:

• DOACs represent a valuable therapeutic option for VTE, offering a favorable safety profile.
• Clinical decisions regarding anticoagulation duration require consideration of multiple patient and disease factors.
• Continued research is essential to fully establish the safety and efficacy of DOACs across diverse clinical situations.